Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

Source: OncLive, November 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the phase II CheckMate-204 trial in metastatic melanoma.

In the expanded portion of the trial, patients with asymptomatic brain metastases as well as those with symptomatic brain metastases who were on low doses of steroids or had just come off of steroid treatment received the combination of nivolumab (Opdivo) and ipilimumab (Yervoy).